Intellia Therapeutics, Inc. (NTLA) Stock Analysis and Metrics

Intellia Therapeutics

NASDAQ: NTLA

$10.73 ▼ -0.37 (-3.33%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.27 Bn

P/E-2.03

P/S19.24

Div. Yield0.00

Add ratio to table…

About

Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies to address serious genetic diseases. The company leverages its proprietary CRISPR/Cas9 platform and delivery technologies to create in vivo and ex vivo therapeutic candidates that target the root cause of diseases. Its core activities involve researching, developing, and advancing product candidates through preclinical and clinical stages with the goal of delivering potentially curative treatments for patients with high unmet medical needs.

The company generates revenue primarily through collaboration agreements, including upfront technology access payments, research funding, milestone payments, and cost reimbursements from collaborators. All revenue to date has been derived from these collaborative arrangements, with no product sales revenue reported as of the filing date. Key collaborators include Regeneron Pharmaceuticals, Inc., with whom Intellia co-develops and co-promotes its ATTR amyloidosis program, as well as other partners such as ONK and Kyverna under separate agreements.

The company operates through the following segments:

• In Vivo Therapeutics.

• Ex Vivo Therapeutics.

Intellia Therapeutics, Inc. is positioned as a pioneer in the clinical development of systemic CRISPR-based therapies, with its lead programs lonvo-z and nex-z representing the first CRISPR-based treatments administered via intravenous infusion for in vivo gene editing in humans. The company competes with other gene editing and genetic medicine companies such as CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics, as well as traditional RNAi and protein-based therapy developers in the HAE and ATTR amyloidosis markets. Its competitive advantages include a modular platform enabling rapid program expansion, deep expertise in delivery technologies like lipid nanoparticles, a strong intellectual property portfolio, and clinical-stage validation of durable therapeutic effects from single-dose treatments.

The company serves patients suffering from severe genetic diseases, including those with hereditary angioedema and transthyretin amyloidosis, as well as individuals with immuno-oncology and autoimmune conditions targeted by its ex vivo programs. Specific customer names are not disclosed in the filing, as the business model relies on therapeutic development and future commercialization rather than direct sales to identifiable clients at this stage.

Investment Thesis

▲ Bull case

Intellia Therapeutics is positioned to revolutionize the treatment landscape for hereditary angioedema with its one-time gene-editing therapy lonvo-z, which demonstrated an 87% reduction in swelling attacks and 62% of patients remaining attack-free at six months in its pivotal Phase 3 trial—outperforming the best available chronic therapies that require lifelong administration and achieve at most a 60% attack-free rate. This durable efficacy, supported by up to three years of follow-up showing no waning of effect in biomarker or clinical outcomes, addresses a profound unmet need where nearly 70% of patients express concern about lifelong therapy and only 20% report being attack-free for a year on current standards of care. The therapy’s potential to eliminate both attack burden and chronic medication use represents a transformative value proposition for patients, physicians, and payers, particularly given the ultra-orphan pricing of existing treatments and the lifetime cost burden measured in multi-millions per patient. With a strong commercial foundation already laid—including scaled field medical teams, payer engagement, and distribution planning—lonvo-z is poised for a BLA submission in the second half of 2026 and a U.S. launch in the first half of 2027, which could unlock significant value given the approximately 7,000 diagnosed HAE patients in the U.S. and the company’s assertion that achieving even a mid-single digit annual market share could generate cash flows sufficient to fully fund operations, reducing reliance on dilutive financing.
The resolution of the clinical hold on the NEWKIND-2 trial for hereditary angioedema-related amyloid cardiomyopathy (ATTTR-CM) represents a critical de-risking event for Intellia’s broader pipeline, as the FDA’s clearance followed implementation of targeted mitigation strategies including enhanced liver monitoring, prophylactic steroid use for early transaminase elevations, and refined exclusion criteria to avoid high-risk patients—measures that directly address the immune-mediated liver injury signal observed in the initial cohort. Although the cardiomyopathy trial remains on hold, the rapid clearance of the neuropathy study (NEWKIND-2) within approximately three to four months of the initial pause, coupled with the company’s proactive engagement with regulators and external experts, suggests a manageable timeline for resolving the cardiomyopathy hold, especially given the distinct patient populations involved—where neuropathy patients are typically younger with fewer comorbidities and a favorable safety profile to date. The company’s ability to resume screening and advance toward full enrollment in NEWKIND-2 by year-end, supported by protocol amendments allowing enrollment of previously screened patients and an increased target from 50 to 60, demonstrates operational resilience and regulatory alignment that could translate into positive intermediate-term news flow, even as the cardiomyopathy program requires further work.
Beyond its lead programs, Intellia’s proprietary CRISPR-based in vivo gene editing platform holds significant long-term value through its potential to expand into additional indications beyond HAE and ATTR amyloidosis, leveraging the same liver-directed delivery system and manufacturing infrastructure already validated in clinical trials. The company’s strategic focus on indications where a one-time treatment could displace costly chronic therapies—such as in other rare liver-expressed diseases—creates a scalable model for future pipeline expansion, supported by existing collaborations and internal discovery efforts. The durability of editing, evidenced by persistent biomarker effects and clinical benefits without observed waning over multiple years, underpins the potential for lifelong therapeutic benefit from a single administration, a differentiation that could command premium pricing and foster durable market share in indications where current therapies require frequent dosing and carry substantial burden. This platform advantage, combined with the company’s financial runway extending into 2027 based on its $605 million cash balance as of end-2025, provides time to advance multiple programs toward clinical proof-of-concept while preserving optionality for partnerships or milestone-driven value creation.

Intellia Therapeutics is positioned to revolutionize the treatment landscape for hereditary angioedema with its one-time gene-editing therapy lonvo-z, which demonstrated an 87% reduction in swelling attacks and 62% of patients remaining attack-free at six months in its pivotal Phase 3 trial—outperforming the best available chronic therapies that require lifelong administration and achieve at most a 60% attack-free rate. This durable efficacy, supported by up to three years of follow-up showing no waning of effect in biomarker or clinical outcomes, addresses a profound unmet need where nearly 70% of patients express concern about lifelong therapy and only 20% report being attack-free for a year on current standards of care. The therapy’s potential to eliminate both attack burden and chronic medication use represents a transformative value proposition for patients, physicians, and payers, particularly given the ultra-orphan pricing of existing treatments and the lifetime cost burden measured in multi-millions per patient. With a strong commercial foundation already laid—including scaled field medical teams, payer engagement, and distribution planning—lonvo-z is poised for a BLA submission in the second half of 2026 and a U.S. launch in the first half of 2027, which could unlock significant value given the approximately 7,000 diagnosed HAE patients in the U.S. and the company’s assertion that achieving even a mid-single digit annual market share could generate cash flows sufficient to fully fund operations, reducing reliance on dilutive financing.
The resolution of the clinical hold on the NEWKIND-2 trial for hereditary angioedema-related amyloid cardiomyopathy (ATTTR-CM) represents a critical de-risking event for Intellia’s broader pipeline, as the FDA’s clearance followed implementation of targeted mitigation strategies including enhanced liver monitoring, prophylactic steroid use for early transaminase elevations, and refined exclusion criteria to avoid high-risk patients—measures that directly address the immune-mediated liver injury signal observed in the initial cohort. Although the cardiomyopathy trial remains on hold, the rapid clearance of the neuropathy study (NEWKIND-2) within approximately three to four months of the initial pause, coupled with the company’s proactive engagement with regulators and external experts, suggests a manageable timeline for resolving the cardiomyopathy hold, especially given the distinct patient populations involved—where neuropathy patients are typically younger with fewer comorbidities and a favorable safety profile to date. The company’s ability to resume screening and advance toward full enrollment in NEWKIND-2 by year-end, supported by protocol amendments allowing enrollment of previously screened patients and an increased target from 50 to 60, demonstrates operational resilience and regulatory alignment that could translate into positive intermediate-term news flow, even as the cardiomyopathy program requires further work.
Beyond its lead programs, Intellia’s proprietary CRISPR-based in vivo gene editing platform holds significant long-term value through its potential to expand into additional indications beyond HAE and ATTR amyloidosis, leveraging the same liver-directed delivery system and manufacturing infrastructure already validated in clinical trials. The company’s strategic focus on indications where a one-time treatment could displace costly chronic therapies—such as in other rare liver-expressed diseases—creates a scalable model for future pipeline expansion, supported by existing collaborations and internal discovery efforts. The durability of editing, evidenced by persistent biomarker effects and clinical benefits without observed waning over multiple years, underpins the potential for lifelong therapeutic benefit from a single administration, a differentiation that could command premium pricing and foster durable market share in indications where current therapies require frequent dosing and carry substantial burden. This platform advantage, combined with the company’s financial runway extending into 2027 based on its $605 million cash balance as of end-2025, provides time to advance multiple programs toward clinical proof-of-concept while preserving optionality for partnerships or milestone-driven value creation.

▼ Bear case

Intellia Therapeutics faces significant near-term execution risk in its hereditary angioedema program despite positive Phase 3 data, as the company’s plans for a BLA submission in the second half of 2026 and U.S. launch in the first half of 2027 hinge on successful navigation of FDA review timelines and potential requests for additional data—particularly given the historical scrutiny of gene therapies for durability and safety, where even minor concerns could trigger delays that compress the commercial window and increase cash burn. The therapy’s premium pricing strategy, while justified by the lifetime cost savings versus chronic therapies, risks triggering payer resistance if perceived as excessive, especially in a landscape where cost-containment pressures are intensifying and payers may scrutinize the long-term durability claims despite the absence of waning in current data, knowing that follow-up beyond three years remains limited and the potential for late-onset immune responses or genomic instability cannot be fully ruled out. Furthermore, the commercial opportunity, while often cited as approximately 7,000 diagnosed patients in the U.S., may be overstated due to undiagnosed or misclassified cases, and the company’s assumption that capturing even a mid-single digit annual market share could fund operations overlooks the upfront commercialization costs—including field force expansion, distribution infrastructure, and reimbursement negotiations—that could strain finances before any revenue materializes, particularly if launch is delayed beyond 2027.
Intellia’s reliance on its liver-directed CRISPR platform for multiple programs creates a concentration risk, as any safety signal arising from the delivery mechanism or editing process—such as the immune-mediated liver toxicity seen in ATTR-CM—could have cross-indication implications that delay or derail other pipeline candidates, even if current data from HAE and neuropathy trials show no similar events. The platform’s use of lipid nanoparticles to deliver editing machinery to hepatocytes, while effective, may provoke immune responses in susceptible individuals that are not fully predictable by current screening methods, and the company’s admission that it lacks biomarkers to identify high-risk patients pre-dose leaves it dependent on reactive monitoring rather than prevention, which could undermine physician and payer confidence if similar events emerge in other trials. Moreover, the competitive landscape is evolving rapidly, with multiple companies advancing RNAi-based therapies (e.g., Alnylam’s Amvuttra, vutrisiran) and emerging gene-editing approaches that may offer comparable efficacy with different risk profiles, potentially diminishing the long-term appeal of a one-time treatment if safety concerns persist or if chronic therapies continue to improve in convenience and effectiveness, thereby eroding the assumed durability advantage of lonvo-z and related candidates.

Intellia Therapeutics faces significant near-term execution risk in its hereditary angioedema program despite positive Phase 3 data, as the company’s plans for a BLA submission in the second half of 2026 and U.S. launch in the first half of 2027 hinge on successful navigation of FDA review timelines and potential requests for additional data—particularly given the historical scrutiny of gene therapies for durability and safety, where even minor concerns could trigger delays that compress the commercial window and increase cash burn. The therapy’s premium pricing strategy, while justified by the lifetime cost savings versus chronic therapies, risks triggering payer resistance if perceived as excessive, especially in a landscape where cost-containment pressures are intensifying and payers may scrutinize the long-term durability claims despite the absence of waning in current data, knowing that follow-up beyond three years remains limited and the potential for late-onset immune responses or genomic instability cannot be fully ruled out. Furthermore, the commercial opportunity, while often cited as approximately 7,000 diagnosed patients in the U.S., may be overstated due to undiagnosed or misclassified cases, and the company’s assumption that capturing even a mid-single digit annual market share could fund operations overlooks the upfront commercialization costs—including field force expansion, distribution infrastructure, and reimbursement negotiations—that could strain finances before any revenue materializes, particularly if launch is delayed beyond 2027.
Intellia’s reliance on its liver-directed CRISPR platform for multiple programs creates a concentration risk, as any safety signal arising from the delivery mechanism or editing process—such as the immune-mediated liver toxicity seen in ATTR-CM—could have cross-indication implications that delay or derail other pipeline candidates, even if current data from HAE and neuropathy trials show no similar events. The platform’s use of lipid nanoparticles to deliver editing machinery to hepatocytes, while effective, may provoke immune responses in susceptible individuals that are not fully predictable by current screening methods, and the company’s admission that it lacks biomarkers to identify high-risk patients pre-dose leaves it dependent on reactive monitoring rather than prevention, which could undermine physician and payer confidence if similar events emerge in other trials. Moreover, the competitive landscape is evolving rapidly, with multiple companies advancing RNAi-based therapies (e.g., Alnylam’s Amvuttra, vutrisiran) and emerging gene-editing approaches that may offer comparable efficacy with different risk profiles, potentially diminishing the long-term appeal of a one-time treatment if safety concerns persist or if chronic therapies continue to improve in convenience and effectiveness, thereby eroding the assumed durability advantage of lonvo-z and related candidates.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password